m6A-centered Crosstalk Information

Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
Crosstalk ID
M6ACROT05435
 [1]
m6A modification hsa-miR-19a-3p hsa-miR-19a-3p METTL14 Methylation : m6A sites Direct Enhancement Non-coding RNA miR-19a Regulated Target  lncRNA       miRNA   circRNA
m6A Modification:
m6A Regulator Methyltransferase-like 14 (METTL14) WRITER
 Regulator Info 
m6A Target hsa-miR-19a-3p
 Targert Gene 
Epigenetic Regulation that have Cross-talk with This m6A Modification:
Epigenetic Regulation Type Non-coding RNA (ncRNA)
Epigenetic Regulator hsa-miR-19a-3p microRNA View Details
Crosstalk Relationship m6A  →  ncRNA Enhancement
Crosstalk Mechanism m6A regulators directly modulate the functionality of ncRNAs through specific targeting ncRNA
Crosstalk Summary METTL14 increased the M6A modification of pri-miR-19a and promoted the processing of mature hsa-miR-19a-3p, thus promoting the proliferation and invasion of atherosclerotic vascular endothelial cells.
Responsed Disease Atherosclerosis ICD-11: BD40
 Disease Info 
Cell Process Cell proliferation
Cell invasion
In-vitro Model
 ASVEC cell line (Atherosclerotic vascular endothelial cells)
Full List of Potential Compound(s) Related to This m6A-centered Crosstalk
BD40: Atherosclerosis 125 Compound(s) Regulating the Disease Click to Show/Hide the Full List
 Compound Name Acipimox Approved [2]
Synonyms
Monted; Nedios; Olbemox; Olbetam; K 9321
    Click to Show/Hide
External Link
CID: 5310993
TTD: D0S1NZ
DrugBank: DB09055
 Compound Name LAROPIPRANT Phase 4 [3]
Synonyms
571170-77-9; MK 0524; Cardaptive; MK-0524; UNII-G7N11T8O78; CHEMBL426559; G7N11T8O78; 2-[(3R)-4-[(4-chlorophenyl)methyl]-7-fluoro-5-methylsulfonyl-2,3-dihydro-1H-cyclopenta[b]indol-3-yl]acetic acid; 2-[(3R)-4-[(4-chlorophenyl)methyl]-7-fluoro-5-methanesulfonyl-1H,2H,3H,4H-cyclopenta[b]indol-3-yl]acetic acid; Tedaptive; Laropiprant [USAN:INN:BAN]; [14C]-Laropiprant; Laropiprant/MK-0524; Laropiprant (INN/USAN); Laropiprant (MK-0524); SCHEMBL991107; AMOT0189; GTPL3356; KS-00000XIE; CTK8F0660; MK-0524B
    Click to Show/Hide
External Link
CID: 9867642
TTD: D0WL5V
DrugBank: DB11629
 Compound Name Anacetrapib Phase 3 [4]
Synonyms
MK0859; Anacetrapib (USAN); MK-0859
    Click to Show/Hide
External Link
CID: 11556427
TTD: D07HLS
DrugBank: DB06630
 Compound Name LY2157299 Phase 2/3 [5]
Synonyms
Galunisertib; 700874-72-2; LY 2157299; LY-2157299; UNII-3OKH1W5LZE; 4-(2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 3OKH1W5LZE; Galunisertib (LY2157299); AK-79916; 4-[5,6-Dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-quinolinecarboxamide; 4-(2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo-[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 4-[2-(6-methylpyridin-2-yl)-4H,5H,6H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxamide
    Click to Show/Hide
External Link
CID: 10090485
TTD: D06TFI
DrugBank: DB11911
 Compound Name PACTIMIBE Phase 2/3 [6]
Synonyms
189198-30-9; UNII-D874R9PZ9T; D874R9PZ9T; CHEMBL478858; Pactimibe [INN:BAN]; [7-(2,2-Dimethylpropanamido)-4,6-dimethyl-1-octylindolin-5-yl]acetic acid; (7-(2,2-Dimethylpropanamido)-4,6-dimethyl-1-octylindolin-5-yl)acetic acid; AC1MIXTD; SCHEMBL282098; CTK0H7032; DTXSID80172315; TXIIZHHIOHVWJD-UHFFFAOYSA-N; ZINC1545445; BDBM50263192; DB12971; 2-[7-(2,2-Dimethylpropanoylamino)-4,6-dimethyl-1-octyl-2,3-dihydroindo L-5-yl]acetic acid; AN-30445; 198P309
    Click to Show/Hide
External Link
CID: 3081927
TTD: D02GWF
DrugBank: DB12971
 Compound Name LY3012212 Phase 2 [7]
Synonyms
Icrucumab
    Click to Show/Hide
External Link
TTD: D0X2RL
 Compound Name K-134 Phase 2 [8]
Synonyms
SULBACTAM; 68373-14-8; sulbactam acid; Sulbactamum; Betamaze; Penicillanic Acid Sulfone; (2S,5R)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid 4,4-dioxide; penicillanic acid 1,1-dioxide; UNII-S4TF6I2330; CP 45899; CHEMBL403; CHEBI:9321; S4TF6I2330; Sulbactam;Penicillanic acid sulfone; (2S,5R)-3,3-Dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid 4,4-dioxide; Sulbactam [INN:BAN]; CP-45,899; Sulbactamum [INN-Latin]; DSSTox_CID_3605; DSSTox_RID_77104
    Click to Show/Hide
External Link
CID: 9908900
TTD: D0S4SX
DrugBank: DB12685
 Compound Name BMS-582949 Phase 2 [9]
Synonyms
623152-17-0; BMS 582949; UNII-CR743OME9E; BMS582949; CR743OME9E; PS540446; CHEMBL1230065; PS-540446; 4-{[5-(cyclopropylcarbamoyl)-2-methylphenyl]amino}-5-methyl-N-propylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide; 3mvl; SCHEMBL254996; GTPL7838; DTXSID90211380; MolPort-044-560-326; EX-A1265; BCP14356; ZINC36475284; s8124; BDBM50327009; AKOS030573299; DB12696; Pyrrolo(2,1-f)(1,2,4)triazine-6-carboxamide, 4-((5-((cyclopropylamino)carbonyl)-2-methylphenyl)amino)-5-methyl-n-propyl-; BMS582949 free base; PS 540446
    Click to Show/Hide
External Link
CID: 10409068
TTD: D0Q0AP
DrugBank: DB12696
 Compound Name VB-201 Phase 2 [10]
External Link
CID: 45138527
TTD: D0N2IE
DrugBank: DB15259
 Compound Name CSL-112 Phase 2 [11]
Synonyms
Reconstituted HDL (acute coronary syndrome), CSL
    Click to Show/Hide
External Link
TTD: D0L8VA
 Compound Name MK-1903 Phase 2 [12]
Synonyms
Second-generation niacin receptor agonists (oral, atherosclerosis), Arena/Merck & Co
    Click to Show/Hide
External Link
CID: 49763030
TTD: D09TGC
 Compound Name DRL-17822 Phase 2 [13]
Synonyms
CETP inhibitor (dyslipidemia/atherosclerosis/cardiovascular diseases), Dr Reddy's
    Click to Show/Hide
External Link
CID: 58689743
TTD: D07UJA
 Compound Name PRC-4016 Investigative [14]
External Link
CID: 78210211
TTD: D03WAT
DrugBank: DB12990
 Compound Name K-604 Phase 2 [15]
Synonyms
BDBM86691
    Click to Show/Hide
External Link
CID: 9892288
TTD: D03PYD
 Compound Name Revacept Phase 2 [16]
Synonyms
Arterial thrombosis treatment, Trigen; PR-15; Antiplatelet protein therapy (arterial thrombosis/atherosclerosis), Trigen
    Click to Show/Hide
External Link
TTD: D03BAC
 Compound Name DVC1-0101 Phase 2 [17]
Synonyms
Ischemia gene therapy, DNAVEC\Kyushu University; FGF2-carrying Sendai virus, DNAVEC\Kyushu University; SeV-FGF2 gene therapy (virus recombinant, ischaemia) DNAVEC\Kyushu University
    Click to Show/Hide
External Link
TTD: D00IZD
 Compound Name ATL-313 Phase 1/2 [18]
Synonyms
DE-112; ATL-313 (ocular disease), Adenosine Therapeutics; ATL-313 (ocular disease), Clinical Data
    Click to Show/Hide
External Link
CID: 11627443
TTD: D08FHZ
DrugBank: DB12295
 Compound Name PSI-697 Phase 1 [19]
Synonyms
UNII-LH1XC916ME; 851546-61-7; LH1XC916ME; CHEMBL219046; 2-(4-Chlorobenzyl)-3-hydroxy-7,8,9,10-tetrahydrobenzo(H)quinoline-4-carboxylic acid; 2-(4-chlorobenzyl)-3-hydroxy-7,8,9,10-tetrahydrobenzo[h]quinoline-4-carboxylic acid; SCHEMBL43527; DIEPFYNZGUUVHD-UHFFFAOYSA-N; ZINC28603970; BDBM50201984; AKOS032945074; CS-5867; DB12211; HY-15526; LS-193902; 2-(4-chloro-benzyl)-3-hydroxy-7,8,9,10-tetrahydro-benzo[h]-quinoline-4-carboxylic acid; 2-(4-Chloro-benzyl)-3-hydroxy-7,8,9,10-tetrahydro-benzo[h]quinoline-4-carboxylic
    Click to Show/Hide
External Link
CID: 12004316
TTD: D0Z0AM
DrugBank: DB12211
 Compound Name SLV-342 Phase 1 [20]
External Link
TTD: D0Y9YG
 Compound Name LXR 623 Phase 1 [21]
Synonyms
LXR-623
    Click to Show/Hide
External Link
CID: 16734800
TTD: D0R4EN
 Compound Name ATR-101 Phase 1 [22]
External Link
CID: 131678
TTD: D0MB2Z
 Compound Name MDCO-216 Phase 1 [23]
External Link
TTD: D0L1ZK
 Compound Name XL-041 Phase 1 [24]
Synonyms
XCT-0179628; XCT-628; XL-652; XL-652); LXR modulator, X-Ceptor Therapeutics; LXR modulators, Exelixis/Sankyo; Liver X receptormodulator, Exelixis/Sankyo; Liver X receptor modulator, X-Ceptor; LXR agonist (atherosclerosis), BMS/Exelixis; LXR modulators, X-Ceptor Therapeutics/Sankyo; Liver X receptor modulator, X-Ceptor Therapeutics/Sankyo; Liver X receptor modulators (cardiovascular disorders), Exelixis/Bristol-Myers Squibb
    Click to Show/Hide
External Link
TTD: D0L0DZ
 Compound Name BMS-852927 Phase 1 [25]
External Link
CID: 49787490
TTD: D0H4DR
 Compound Name CS-8080 Phase 1 [26]
Synonyms
Liver X receptor modulator (artherosclerosis), Daiichi Sankyo Inc; LXR modulator (anti-arteriosclerotic), Daiichi Sankyo Inc
    Click to Show/Hide
External Link
CID: 16212738
TTD: D0GY1Y
 Compound Name ISIS-APOCIII Phase 1 [27]
External Link
TTD: D0F6KM
 Compound Name Rilapladib Phase 1 [28]
External Link
CID: 9918381
TTD: D05GZD
DrugBank: DB05119
 Compound Name BMS-779788 Phase 1 [29]
External Link
CID: 59251511
TTD: D00QWU
 Compound Name BAY-60-5521 Phase 1 [30]
Synonyms
CETP inhibitors (dyslipidemia), Bayer; Cholesteryl ester transfer protein inhibitors (dyslipidemia), Bayer
    Click to Show/Hide
External Link
CID: 11691871
TTD: D00JQE
 Compound Name Quinazoline derivative 13 Patented [31]
Synonyms
PMID26936077-Compound-24
    Click to Show/Hide
External Link
CID: 60161489
TTD: D0P2BJ
 Compound Name Darapladib Discontinued in Phase 3 [32]
Synonyms
SB 480848; Darapladib (USAN)
    Click to Show/Hide
External Link
CID: 9939609
TTD: D0L5UO
DrugBank: DB06311
 Compound Name Acifran Discontinued in Phase 3 [33]
Synonyms
Reductol; AY-25712
    Click to Show/Hide
External Link
CID: 51576
TTD: D0K1HO
 Compound Name ET-642 Discontinued in Phase 2 [34]
Synonyms
ETC-642; RLT peptide, Esperion; RLT peptide, Pfizer
    Click to Show/Hide
External Link
TTD: D0S3MY
 Compound Name SQ-32709 Discontinued in Phase 2 [35]
Synonyms
farnesyl diphosphate; farnesyl pyrophosphate; (2E,6E)-Farnesyl diphosphate; trans,trans-Farnesyl diphosphate; all-trans-Farnesyl pyrophosphate; (all-E)-Farnesyl diphosphate; (E,E)-Farnesyl pyrophosphate; (2E,6E)-Farnesyl pyrophosphate; trans-Farnesyl pyrophosphate; 2-trans,6-trans-Farnesyl pyrophosphate; farnesyl-PP; (E,E)-Farnesyl diphosphate; 2-trans,6-trans-farnesyl diphosphate; trans-trans-farnesyl diphosphate; UNII-79W6B01D07; CHEBI:17407; trans,trans-Farnesyl pyrophosphate; Sq 32709; 13058-04-3; CHEMBL69330
    Click to Show/Hide
External Link
CID: 445713
TTD: D0N5HO
DrugBank: DB07780
 Compound Name CETi-1 Discontinued in Phase 2 [36]
Synonyms
Cholesteryl Ester Transfer Protein Vaccine; CETP vaccine, T Cell Sciences; Vaccine (CETP), AVANT; Vaccine (CETP), T Cell Sciences; Vaccine (atherosclerosis), T Cell Sciences
    Click to Show/Hide
External Link
TTD: D0J4KC
 Compound Name Gantofiban Discontinued in Phase 2 [37]
Synonyms
CHEMBL78871; BDBM50092103; (4-{3-[4-(Imino-methoxycarbonylamino-methyl)-phenyl]-2-oxo-oxazolidin-5-ylmethyl}-piperazin-1-yl)-acetic acid ethyl ester(EMD-122347); (4-{(R)-3-[4-(Imino-methoxycarbonylamino-methyl)-phenyl]-2-oxo-oxazolidin-5-ylmethyl}-piperazin-1-yl)-acetic acid ethyl ester
    Click to Show/Hide
External Link
CID: 135565976
TTD: D0H9WO
 Compound Name FCP-3P1 Discontinued in Phase 2 [38]
Synonyms
CardioRex; Antihyperlipidemic, Forbes Medi-Tech
    Click to Show/Hide
External Link
CID: 60496
TTD: D0H7WA
 Compound Name Lifibrol Discontinued in Phase 2 [39]
Synonyms
K-12148; U-83860; (R)-Lifibrol; (S)-Lifibrol; (S)-Lifibrol methyl ester
    Click to Show/Hide
External Link
CID: 57112
TTD: D0BC4Q
DrugBank: DB12448
 Compound Name TA-7552 Discontinued in Phase 2 [40]
Synonyms
TA 7552; 104756-72-1; 1-(3,4-Dimethoxyphenyl)-2,3-bis(methoxycarbonyl)-4-hydroxy-6,7,8-trimethoxynaphthalene; AC1L2U74; SCHEMBL8688163; DTXSID60146695; DTCYXOLBEPGOHV-UHFFFAOYSA-N; HY-100253; CS-0018404; dimethyl 4-(3,4-dimethoxyphenyl)-1-hydroxy-5,6,7-trimethoxynaphthalene-2,3-dicarboxylate; 2,3-Naphthalenedicarboxylic acid, 4-(3,4-dimethoxyphenyl)-1-hydroxy-5,6,7-trimethoxy-, dimethyl ester
    Click to Show/Hide
External Link
CID: 128664
TTD: D02RVE
 Compound Name RUS 3108 Discontinued in Phase 1 [41]
External Link
TTD: D0ZD6Y
 Compound Name GR-328713 Discontinued in Phase 1 [42]
Synonyms
GW-320449X; GW-328713X
    Click to Show/Hide
External Link
TTD: D0SS6J
 Compound Name RG7418 Discontinued in Phase 1 [43]
Synonyms
BI204
    Click to Show/Hide
External Link
TTD: D0MH1R
 Compound Name PF-3052334 Discontinued in Phase 1 [44]
Synonyms
SCHEMBL3959323
    Click to Show/Hide
External Link
CID: 24742042
TTD: D0MF7U
 Compound Name Goxalapladib Discontinued in Phase 1 [45]
Synonyms
Goxalapladib < USAN; 2-[2-[2-(2,3-Difluorophenyl)ethyl]-4-oxo-1,4-dihydro-1,8-naphthyridin-1-yl]-N-[1-(2-methoxyethyl)piperidin-4-yl]-N-[4'-(trifluoromethyl)biphenyl-4-ylmethyl]acetamide
    Click to Show/Hide
External Link
CID: 11686305
TTD: D0MC3R
 Compound Name AC3056 Discontinued in Phase 1 [46]
External Link
TTD: D0L8OE
 Compound Name PF-3185043 Discontinued in Phase 1 [47]
External Link
TTD: D0K3GU
 Compound Name GSK568859 Discontinued in Phase 1 [48]
External Link
TTD: D0CA3J
 Compound Name NICANARTINE Discontinued in Phase 1 [49]
Synonyms
MRZ-3/124; 2,6-Di-tert-butyl-4-[3-(3-pyridylmethoxy)propyl]phenol
    Click to Show/Hide
External Link
CID: 66001
TTD: D0A0FG
 Compound Name LG-101280 Discontinued in Phase 1 [50]
Synonyms
LSN-862; LY-WWW; LY-YYY; PPAR modulators, Ligand/Lilly
    Click to Show/Hide
External Link
TTD: D09SLU
 Compound Name PF-3491165 Discontinued in Phase 1 [51]
Synonyms
PF-03491165
    Click to Show/Hide
External Link
TTD: D09QIJ
 Compound Name SB-435495 Discontinued in Phase 1 [52]
External Link
CID: 10417440
TTD: D09NBM
 Compound Name P-0654 Discontinued in Phase 1 [53]
Synonyms
P-0655
    Click to Show/Hide
External Link
TTD: D07IXD
 Compound Name CL-277082 Discontinued in Phase 1 [54]
Synonyms
UNII-KOF50RA8PQ; KOF50RA8PQ; CHEMBL277986; 3-(2,4-difluorophenyl)-1-[4-(2,2-dimethylpropyl)benzyl]-1-heptylurea; Ddpmhu; AC1Q5MV2; AC1L2PE2; SCHEMBL408973; CTK8D5698; BDBM50022279; ZINC36330844; CL 277082; N'-(2,4-DIFLUOROPHENYL)-N-HEPTYL-N-(4-NEOPENTYLBENZYL)UREA; Urea, N'-(2,4-difluorophenyl)-N-((4-(2,2-dimethylpropyl)phenyl)methyl)-N-heptyl-; 3-(2,4-difluorophenyl)-1-[[4-(2,2-dimethylpropyl)phenyl]methyl]-1-heptylurea; 3-(2,4-Difluoro-phenyl)-1-[4-(2,2-dimethyl-propyl)-benzyl]-1-heptyl-urea
    Click to Show/Hide
External Link
CID: 125893
TTD: D06FCR
 Compound Name LF-08-0133 Discontinued in Phase 1 [55]
External Link
TTD: D04ZNG
 Compound Name PF-807925 Discontinued in Phase 1 [56]
External Link
TTD: D04GVN
 Compound Name F-1394 Discontinued in Phase 1 [57]
Synonyms
AC1OCF5R; SCHEMBL4296509; [(1S,2S)-2-[[2,2-dimethylpropyl(nonyl)carbamoyl]amino]cyclohexyl] 3-[(2,2,5,5-tetramethyl-1,3-dioxane-4-carbonyl)amino]propanoate
    Click to Show/Hide
External Link
CID: 6918210
TTD: D03QZB
 Compound Name CP-800569 Discontinued in Phase 1 [58]
Synonyms
(2R)-3-[3-(4-chloro-3-ethylphenoxy)-N-[[3-(1,1,2,2-tetrafluoroethoxy)phenyl]methyl]anilino]-1,1,1-trifluoropropan-2-ol
    Click to Show/Hide
External Link
CID: 6918520
TTD: D03MAD
 Compound Name APP-018 Discontinued in Phase 1 [59]
Synonyms
D-4F; Apolipoprotein A1 mimetic (atherosclerosis), Bruin Pharma; Apolipoprotein A1 mimetic (atherosclerosis),Novartis
    Click to Show/Hide
External Link
CID: 72941823
TTD: D03FPA
 Compound Name Nobiletin Preclinical [60]
Synonyms
478-01-3; Hexamethoxyflavone; 3',4',5,6,7,8-Hexamethoxyflavone; 5,6,7,8,3',4'-Hexamethoxyflavone; UNII-D65ILJ7WLY; 2-(3,4-Dimethoxyphenyl)-5,6,7,8-tetramethoxy-4H-1-benzopyran-4-one; 2-(3,4-dimethoxyphenyl)-5,6,7,8-tetramethoxychromen-4-one; NSC-76751; D65ILJ7WLY; 2-(3,4-dimethoxyphenyl)-5,6,7,8-tetramethoxy-4H-chromen-4-one; CHEMBL76447; Nobiletin (Hexamethoxyflavone); CHEBI:7602; NSC76751; MFCD03273560; Flavone, 5,6,7,8,3',4'-hexamethoxy; 4H-1-Benzopyran-4-one, 2-(3,4-dimethoxyphenyl)-5,6,7,8-tetramethoxy-; SMR000156231; CCRIS 9012; NSC 76751; CPD000156231; Nobiletin, >=97%; Spectrum2_001697; Spectrum3_000921; Spectrum4_001020; KBioGR_001519; MLS000574877; MLS000759462; MLS000877030; MLS001424129; Nobiletin, analytical standard; SCHEMBL244029; SPECTRUM1505268; SPBio_001654; MEGxp0_000930; ACon1_000921; KBio3_001922; DTXSID30197275; 2-(3,4-dimethoxyphenyl)-5,6,7,8-tetramethoxy-chromen-4-one; HMS2051D09; HMS2234A09; HMS3373C14; HMS3393D09; HMS3651G20; HY-N0155; ZINC1531669; 3'4'5,6,7,8-Hexamethoxyflavone; 3,4,5,6,7,8-Hexamethoxyflavone; ANW-42631; BDBM50338976; CCG-38781; CN0043; LMPK12111468; NSC618903; STL565829; AKOS015965334; NOBILETIN, 20% (Technical Grade); AC-1023; CS-5518; MCULE-1015144950; NC00186; NSC-618903; SDCCGMLS-0066776.P001; NCGC00095703-01; NCGC00095703-02; NCGC00169228-01; 5,6,7,8,3'',4''-hexamethoxyflavone; AK168175; AS-17452; NCI60_041691; DB-050181; FT-0686667; N0871; N1311; S2333; SW197566-2; V0181; C10112; SR-01000712262; Q-100511; Q2402963; SR-01000712262-5; BRD-K06753942-001-02-0; 2-(3,4-Dimethoxy-phenyl)-5,6,7,8-tetramethoxy-chromen-4-one; 4H-1-Benzopyran-4-one,4-dimethoxyphenyl)-5,6,7,8-tetramethoxy-; 2-(3,4-Dimethoxyphenyl)-5,6,7,8-tetramethoxy-4H-1-benzopyran-4-one, 9CI; 3 inverted exclamation mark ,4 inverted exclamation mark ,5,6,7,8-HEXAMETHOXYFLAVONE; 4H-1-Benzopyran-4-one, 2-(3,4-dimethoxyphenyl)-5,6,7,8-tetramethoxy- (9CI)
    Click to Show/Hide
External Link
CID: 72344
TTD: D4PG6A
 Compound Name Quinoxaline Preclinical [61]
Synonyms
WYE-111672; WYE-672
    Click to Show/Hide
External Link
CID: 7045
TTD: D0U9RR
 Compound Name HL-004 Preclinical [62]
Synonyms
TS-962
    Click to Show/Hide
External Link
CID: 6426883
TTD: D09MJO
 Compound Name ETX-6107 Preclinical [63]
Synonyms
ETS-6107; ETS-6114; Antihypercholesterolemic agents (atherosclerosis), e-Therapeutics
    Click to Show/Hide
External Link
TTD: D05YRV
 Compound Name BAY-38-1315 Preclinical [64]
Synonyms
BAY-19-4789
    Click to Show/Hide
External Link
CID: 46880878
TTD: D05QXT
 Compound Name 2164U90 Terminated [65]
Synonyms
BW-2164; BW-2164U90
    Click to Show/Hide
External Link
CID: 9841699
TTD: D0ZJ0A
 Compound Name GT-16-239 Terminated [66]
External Link
TTD: D0YQ9G
 Compound Name Cholazol Terminated [67]
Synonyms
Cholestran
    Click to Show/Hide
External Link
TTD: D0XY4Q
 Compound Name BB-476 Terminated [68]
External Link
CID: 9803625
TTD: D0WU8Z
 Compound Name CGP-43371 Terminated [69]
Synonyms
Cgp 43371; UNII-V97741GKF2; V97741GKF2; 123036-23-7; cgp43371; N,15-Didehydro-15-deoxo-1-deoxy-1,15-epoxy-4-O-methyl-3-(4-((2,4,6-trimethyl)methyl)-1-piperazinyl)rifamycin 8-(2,2-dimethylpropanoate); Rifamycin, N,15-didehydro-15-deoxo-1-deoxy-1,15-epoxy-3-(4-((2,4,6-trimethylphenyl)methyl)-1-piperazinyl)-, 8-(2,2-dimethylpropanoate)
    Click to Show/Hide
External Link
CID: 6441203
TTD: D0U8KA
 Compound Name AL-0671 Terminated [70]
Synonyms
AL-0670
    Click to Show/Hide
External Link
CID: 57415651
TTD: D0TB1X
 Compound Name BIBX-79 Terminated [71]
Synonyms
175033-26-8; AC1L9UY2; BIBX 79; SCHEMBL8046646; SCHEMBL3363189; CHEMBL2377448; CHEMBL3765649; MolPort-028-951-512; ZINC59696570; ZINC238856506; ZINC100502012; AKOS034800865; MCULE-9414485243; EN300-155171; Z1768160684; 4-chloro-N-[4-[4-(dimethylaminomethyl)phenyl]cyclohexyl]-N-methyl-benzamide; 4-chloro-N-[4-[4-(dimethylaminomethyl)phenyl]cyclohexyl]-N-methylbenzamide; 4-Chloro-N-[4-(4-dimethylaminomethyl-phenyl)-cyclohexyl]-N-methyl-benzamide
    Click to Show/Hide
External Link
CID: 501396
TTD: D0S1XO
 Compound Name CI-999 Terminated [72]
Synonyms
PD-138142-15
    Click to Show/Hide
External Link
CID: 74083365
TTD: D0PG0S
 Compound Name Bio-Flow Terminated [73]
External Link
TTD: D0P1JV
 Compound Name CGS-24565 Terminated [74]
Synonyms
Cgs 24565; 136583-72-7; N,15-Didehydro-11,15-dideoxo-1-deoxy-1,15-epoxy-11-hydroxy-4-O-methyl-3-(4-((2,4,6-trimethylphenyl)methyl)-1-piperazinyl)rifamycin 8-(2,2-dimethylpropanoate); Rifamycin, N,15-didehydro-11,15-dideoxo-1-deoxy-1,15-epoxy-11-hydroxy-4-O-methyl-3-(4-((2,4,6-trimethylphenyl)methyl)-1-piperazinyl)-, 8-(2,2-dimethylpropanoate)
    Click to Show/Hide
External Link
CID: 6443293
TTD: D0OL9V
 Compound Name TEI-6522 Terminated [75]
External Link
CID: 9953017
TTD: D0OK8M
 Compound Name FR-145237 Terminated [76]
External Link
CID: 9850056
TTD: D0O2AC
 Compound Name Squalestatin 1 Terminated [77]
Synonyms
Zaragozic acid A; Squalestatin; 142561-96-4; ZARAGOZIC ACIDS A; UNII-1117HVX02L; CHEMBL280978; CHEBI:75170; 1117HVX02L; 1S-((4S-acetoxy-5R-methyl-3-methylene-6-phenylhexyl)-6-(E)-4S,6S-dimethyloct-2-enoyloxy)-4,7S-dihydroxy-2,8-dioxabicyclo[321]octane-3S,4S,5R-tricarboxylic acid; L-erythro-L-glycero-D-altro-7-Trideculo-7,4-furanosonic acid, 2,7-anhydro-3,4-di-C-carboxy-8,9,10,12,13-pentadeoxy-10-methylene-12-(phenylmethyl)-, 11-acetate 5-(4,6-dimethyl-2-octenoate), (5(2E,4S,6S),7S)-; Squalestatin 1, Glaxo; Zaragozic acid A, Glaxo
    Click to Show/Hide
External Link
CID: 6438355
TTD: D0O1AV
 Compound Name F-12509A Terminated [78]
External Link
CID: 9862964
TTD: D0O0JH
 Compound Name TA-993 Terminated [79]
Synonyms
MB-3, Tanabe
    Click to Show/Hide
External Link
CID: 129579
TTD: D0M9CV
 Compound Name Barixibat Terminated [80]
Synonyms
BARI-1453; Bile acid resorption inhibitor, Aventis; HMR-1453; 1453, Aventis
    Click to Show/Hide
External Link
CID: 10234172
TTD: D0LV0R
 Compound Name PD-146176 Terminated [81]
Synonyms
PD 146176; 4079-26-9; 6,11-dihydrothiochromeno[4,3-b]indole; 6,11-Dihydro[1]benzothiopyrano[4,3-b]indole; CHEMBL180917; pd146176; NSC168807; 6,3-b]indole; NSC 168807; AC1L6RUM; 6,11-Dihydro-5-thia-11-aza-benzo(a)fluorene; SCHEMBL1986281; ZINC6892; CTK4I3773; AOB5548; MolPort-003-959-269; BCP24885; BS0260; BDBM50208823; MFCD05664738; AKOS024457313; NSC-168807; [1]Benzothiopyrano[4, 6,11-dihydro-; NCGC00165868-01; B7208; PD 146176, &gt; (1)Benzothiopyrano(4,3-b)indole, 6,11-dihydro-
    Click to Show/Hide
External Link
CID: 297589
TTD: D0J8RS
 Compound Name BIBB-515 Terminated [82]
Synonyms
BIBB 515; 156635-05-1; UNII-CG2Q6688S4; CHEMBL417571; CG2Q6688S4; (4-Chloro-phenyl)-{4-[4-(4,5-dihydro-oxazol-2-yl)-benzylidene]-piperidin-1-yl}-methanone; (4-chloro-phenyl)-(4-[4-(4,5-dihydro-oxazol-2-yl)-benzylidene]-piperidin-1-yl)-methanone; AC1L9UY8; SCHEMBL3676833; CTK8E8258; DTXSID00333401; MolPort-009-019-333; ZINC598970; BDBM50128071; RT-011501; J-009325; 1-(4-Chlorobenzoyl)-4-((4-(2-oxazolin-2-yl) benzylidene))piperidine; Piperidine, 1-(4-chlorobenzoyl)-4-((4-(4,5-dihydro-2-oxazolyl)phenyl)methylene)-
    Click to Show/Hide
External Link
CID: 501398
TTD: D0I2YV
 Compound Name LF-7-0165c Terminated [83]
External Link
TTD: D0EA7H
 Compound Name SDZ-267-489 Terminated [84]
External Link
TTD: D0D2RZ
 Compound Name WAY-121898 Terminated [85]
Synonyms
136100-14-6; 1-Piperidinecarboxylic acid, 4-methyl-, 4-phenoxyphenyl ester; ACMC-20mw0l; SCHEMBL2597837; CHEMBL267052; ZINC14493; CTK0F3948; DTXSID30430876; 4-PHENOXYPHENYL 4-METHYL-1-PIPERIDINECARBOXYLATE
    Click to Show/Hide
External Link
CID: 9796754
TTD: D0CS0D
 Compound Name SR12813 Terminated [86]
Synonyms
SR 12813; 126411-39-0; SR-12813; CHEBI:77317; GW 485801; CHEMBL458767; [2-(3,5-DI-TERT-BUTYL-4-HYDROXY-PHENYL)-1-(DIETHOXY-PHOSPHORYL)-VINYL]-PHOSPHONIC ACID DIETHLYL ESTER; 4-[2,2-bis(diethoxyphosphoryl)ethenyl]-2,6-ditert-butylphenol; Tetraethyl 2-(3,5-di-tert-butyl-4-hydroxyphenyl)ethenyl-1,1-bisphosphonate; tetraethyl [2-(3,5-di-tert-butyl-4-hydroxyphenyl)ethene-1,1-diyl]bis(phosphonate); [[3,5-Bis(1,1-dimethylethyl)-4-hydroxyphenyl]ethenylidene]bis-phosphonic acid tetraethyl ester; SRL; 1ilh; AC1L9JHO
    Click to Show/Hide
External Link
CID: 446313
TTD: D0C7RV
DrugBank: DB04466
 Compound Name CP-230821 Terminated [87]
External Link
TTD: D08MAR
 Compound Name T-686 Terminated [88]
Synonyms
PAI-1 inhibitor, Tanabe
    Click to Show/Hide
External Link
CID: 6438903
TTD: D08EIX
 Compound Name RPR-101821 Terminated [89]
External Link
TTD: D08ALQ
 Compound Name MDL-29311 Terminated [90]
Synonyms
MDL-27272; MDL-29097
    Click to Show/Hide
External Link
CID: 131127
TTD: D07YUY
 Compound Name CP-83101 Terminated [91]
Synonyms
AC1O5PZP; SCHEMBL1660808; SCHEMBL1660809; 3,5-Dihydroxy-9,9-diphenyl-6,8-nonadienoate; methyl (3R,5S,6E)-3,5-dihydroxy-9,9-diphenylnona-6,8-dienoate; 6,8-Nonadienoic acid, 3,5-dihydroxy-9,9-diphenyl-, methyl ester, (R*,S*-(E))-(+-)-
    Click to Show/Hide
External Link
CID: 6438614
TTD: D07QSA
 Compound Name INCB3344 Terminated [92]
Synonyms
INCB-3268; INCB-3344; PF-4254196; CCR2 antagonists, Incyte/Pfizer
    Click to Show/Hide
External Link
CID: 10008367
TTD: D07KIJ
 Compound Name CGS-23425 Terminated [93]
Synonyms
CHEMBL46882; N-[3,5-dimethyl-4-(4'-hydroxy-3'-isopropylphenoxy)-phenyl]-oxamic acid; cgs23425; SCHEMBL281877; DTXSID7040998; NOCAS_40998; CGS 23425; BDBM50036402; AKOS027327083; N-[4-(4-Hydroxy-3-isopropyl-phenoxy)-3,5-dimethyl-phenyl]-oxalamic acid; N-[3,5-dimethyl-4-(4''-hydroxy-3''-isopropylphenoxy)phenyl]oxamic acid; ({4-[4-hydroxy-3-(propan-2-yl)phenoxy]-3,5-dimethylphenyl}amino)(oxo)acetic acid
    Click to Show/Hide
External Link
CID: 9874938
TTD: D07EGS
 Compound Name RP-73163 Terminated [94]
Synonyms
CHEMBL434418; BDBM50106700
    Click to Show/Hide
External Link
CID: 44356696
TTD: D06KFR
 Compound Name Astenose Terminated [95]
Synonyms
GM-1077; GMI-077
    Click to Show/Hide
External Link
TTD: D05HHP
 Compound Name S-12340 Terminated [96]
Synonyms
S12340; S 12340; 144754-35-8; SCHEMBL4782175; 8-(3-(3,5-Diterbutyl-4-hydroxyphenylthio)propyl)-1-oxa-2-oxo-3,8-diazaspiro(4.5)decane; 8-(3-(3,5-Di-tert-butyl-4-hydroxyphenylthio)propyl)-1-oxa-2-oxo-3,8-diazaspiro(4.5)decane; 1-Oxa-3,8-diazaspiro(4.5)decan-2-one, 8-(3-((3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl)thio)propyl)-
    Click to Show/Hide
External Link
CID: 9802991
TTD: D04NSW
 Compound Name ZD-9720 Terminated [97]
Synonyms
ZD-7851
    Click to Show/Hide
External Link
TTD: D04GJX
 Compound Name IL1aQb Terminated [98]
Synonyms
IL1aQb therapeutic vaccines (atherosclerosis); CYT-018-IL1aQb; IL1aQb therapeuticvaccines (atherosclerosis), Cytos; Immunodrug vaccines (atherosclerosis), Cytos
    Click to Show/Hide
External Link
TTD: D03VFV
 Compound Name NTE-122 Terminated [99]
Synonyms
ACAT inhibitor, Nissin Food
    Click to Show/Hide
External Link
CID: 9830692
TTD: D03JRJ
 Compound Name B-5354a Terminated [100]
Synonyms
B-5354b; B-5354c; Sphingosine kinase inhibitors, Sankyo
    Click to Show/Hide
External Link
TTD: D02YQJ
 Compound Name F-2833 Terminated [101]
Synonyms
107430-45-5; F 2833; 2-[4-(2-chlorophenyl)phenyl]propan-2-ol; AC1L3UIQ; (2-Chloro-2'-(1,1')-4-biphenyl)-2-propanol; SCHEMBL10802061; DTXSID80148050; f2833; (1,1'-Biphenyl)-4-methanol, 2'-chloro-alpha,alpha-dimethyl-
    Click to Show/Hide
External Link
CID: 147118
TTD: D00QOG
 Compound Name LF-13-0491c Terminated [102]
External Link
TTD: D00KXQ
 Compound Name FR-129169 Terminated [103]
External Link
CID: 9803486
TTD: D00KQT
 Compound Name AM-1101 Investigative [14]
Synonyms
Lactosylceramide synthase inhibitors (hyperproliferative disorders), Amalyte Pharmaceuticals; GAL T-2 inhibitors (hyperproliferative disorders), Amalyte Pharmaceuticals
    Click to Show/Hide
External Link
TTD: D0Y9PQ
 Compound Name Apovasc Investigative [14]
Synonyms
CM-121; CM-125; CM-121 + CM-125
    Click to Show/Hide
External Link
TTD: D0Y3TX
 Compound Name KY-382 Investigative [104]
External Link
CID: 10454368
TTD: D0V9MG
 Compound Name Adiponectin mimetics Investigative [14]
Synonyms
Adiponectin mimetics (oral, type 2 diabetes/atherosclerosis/muscle metabolic diseases)
    Click to Show/Hide
External Link
TTD: D0R1DX
 Compound Name HL-135 Investigative [14]
External Link
TTD: D0Q9RW
 Compound Name KM-011 Investigative [14]
Synonyms
Apo-A1 mimetic peptide (atherosclerosis), KineMed; Apolipoprotein-A1 mimetic peptide (atherosclerosis), KineMed
    Click to Show/Hide
External Link
TTD: D0Q6OL
 Compound Name VULM-1457 Investigative [104]
Synonyms
Acyl CoA cholesterol acyltransferase inhibitor (dyslipidemia/atherosclerosis), Univerzity Komenskeho v Bratislave
    Click to Show/Hide
External Link
TTD: D0OH1O
 Compound Name ARI-1778 Investigative [14]
Synonyms
KH-01503; Rev-D-4F; Reverse-D-4F; Apo-A1 agonist (atherosclerosis), Kos Pharmaceuticals; Apolipoprotein-A1 agonist (atherosclerosis), Abbott; Apolipoprotein-A1 agonist (atherosclerosis), Kos Pharmaceuticals; Apolipoprotein-A1 mimetic peptide (atherosclerosis), Abbott; Apolipoprotein-A1 mimetic peptide (atherosclerosis), Kos Pharmaceuticals; Apo-A1 agonist (atherosclerosis), Abbott/Arisaph
    Click to Show/Hide
External Link
TTD: D0K7VM
 Compound Name GSK-1344386B Investigative [105]
Synonyms
CCR2 antagonist (atherosclerosis); CCR2 antagonist (atherosclerosis), GlaxoSmithKline
    Click to Show/Hide
External Link
TTD: D0C5XF
 Compound Name SCH-602539 Investigative [106]
Synonyms
UNII-7467O90MW3; CHEMBL1270738; 7467O90MW3; SCH602539; 618385-42-5; SCHEMBL8058894; BDBM50329618; Carbamic acid, N-((1R,3aR,4aR,6R,8aR,9S,9aS)-9-((1E)-2-(2,3'-bipyridin)-6'-ylethenyl)dodecahydro-1-methyl-3-oxonaphtho(2,3-C)furan-6-yl)-, ethyl ester; Ethyl ((1R,3aR,4aR,6R,8aR,9S,9aS)-9-((E)-2-(2,3'-bipyridin-6'-yl)vinyl)-1-methyl-3-oxododecahydronaphtho(2,3-C)furan-6-yl}carbamate; Carbamic acid, ((1R,3aR,4aR,6R,8aR,9S,9aS)-9-((1E)-2-(2,3'-bipyridin)-6'-ylethenyl)dodecahydro-1-methyl-3-oxonaphtho(2,3-C)fura
    Click to Show/Hide
External Link
CID: 16214871
TTD: D0BV3B
 Compound Name Radiolabeled VEGF Investigative [14]
Synonyms
Lu-scVEGF; Radiolabeled VEGF (cancer); Radiolabeled VEGF (cancer), Sibtech/Stanford; Technetium-99m-HYNIC-VEGF; Technetium-99m-single chain-VEGF; Lu-177-DOTA-PEG-scVEGF; 99mTc-HYNIC-VEGF; 99mTc-singlechain-VEGF
    Click to Show/Hide
External Link
TTD: D0AT5Y
 Compound Name AG-4070 Investigative [14]
Synonyms
LXR agonists (atherosclerosis); LXR agonists (atherosclerosis), F.Hoffmann-La Roche
    Click to Show/Hide
External Link
TTD: D0A6WQ
 Compound Name Integrin alpha-V/beta-3 receptor mab Investigative [14]
Synonyms
Integrin alpha-V/beta-3 receptor mAb (atherosclerosis); Integrin alpha-V/beta-3 antagonist (atherosclerosis), Vascular Pharmaceuticals; Integrin alpha-V/beta-3 receptor mAb (atherosclerosis), Vascular Pharmaceuticals
    Click to Show/Hide
External Link
TTD: D0A5CH
 Compound Name ICI-245991 Investigative [14]
External Link
TTD: D0A1DT
 Compound Name MK-6892 Investigative [107]
Synonyms
Nicotinic acid 1 receptor (GPR109A) agonists, Merck
    Click to Show/Hide
External Link
CID: 135416394
TTD: D09ZPN
 Compound Name BMS-753951 Investigative [14]
Synonyms
Gadolinium chelate MR imaging agent (atherosclerosis), BMS
    Click to Show/Hide
External Link
TTD: D09WMV
 Compound Name TGFTX-1 Investigative [14]
External Link
TTD: D09OSM
 Compound Name INV-400 Investigative [14]
Synonyms
INV-403; INV-404; INV-405; Invasc-400 series; SREBP transcription factor 2 stimulator (atherosclerosis), InVasc; Sterol regulatory element-binding protein 2 stimulator (atherosclerosis), InVasc
    Click to Show/Hide
External Link
TTD: D09DJS
 Compound Name GX-401 Investigative [14]
External Link
TTD: D07RME
 Compound Name RP-805 Investigative [14]
Synonyms
Matrix metalloproteinase inhibitor (atherosclerosis); Matrix metalloproteinase inhibitor (atherosclerosis), Lantheus; RP-782-111In; Indium-111-RP-782; Technetium-99m-RP-805; Matrix metalloproteinase (MMP) inhibitor (tumor imaging), Bristol-Myers Squibb; 111In-RP-782; 99mTc-RP-805
    Click to Show/Hide
External Link
TTD: D03YMD
 Compound Name RXP-470 Investigative [108]
Synonyms
MMP-12 inhibitors (atherosclerosis); MMP-12 inhibitors (atherosclerosis), CEA; RXP-470 derivatives (atherosclerosis), CEA
    Click to Show/Hide
External Link
CID: 102258832
TTD: D03QXD
 Compound Name 2NTX-99 Investigative [14]
Synonyms
Thromboxane A2 synthesis inhibitor (thrombosis/atherosclerosis), Nile; Thromboxane A2 synthesis inhibitor (thrombosis/atherosclerosis), University of Milano
    Click to Show/Hide
External Link
CID: 10224454
TTD: D02SAK
 Compound Name BAY-1006451 Investigative [14]
Synonyms
[18F]-BAY-1006451
    Click to Show/Hide
External Link
TTD: D01FJN
References
Ref 1 METTL14 regulates M6A methylation-modified primary miR-19a to promote cardiovascular endothelial cell proliferation and invasion. Eur Rev Med Pharmacol Sci. 2020 Jun;24(12):7015-7023. doi: 10.26355/eurrev_202006_21694.
Ref 2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1596).
Ref 3 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800023729)
Ref 4 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8400).
Ref 5 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7797).
Ref 6 ClinicalTrials.gov (NCT00151788) Efficacy and Safety of the ACAT Inhibitor CS-505 (Pactimibe) for Reducing the Progression of Carotid Artery Disease. This Study is Also Known as CAPTIVATE.. U.S. National Institutes of Health.
Ref 7 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800024862)
Ref 8 ClinicalTrials.gov (NCT00783081) Safety and Efficacy of K-134 for the Treatment of Intermittent Claudication. U.S. National Institutes of Health.
Ref 9 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7838).
Ref 10 VB-201, an oxidized phospholipid small molecule, inhibits CD14- and Toll-like receptor-2-dependent innate cell activation and constrains atherosclerosis. Clin Exp Immunol. 2014 Jan;175(1):126-37.
Ref 11 ClinicalTrials.gov (NCT02108262) A Phase 2b Study of CSL112 in Subjects With Acute Myocardial Infarction.. U.S. National Institutes of Health.
Ref 12 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5785).
Ref 13 ClinicalTrials.gov (NCT01388816) A Safety and Efficacy Study of DRL-17822, a Cholesteryl Ester Transfer Protein (CETP) Inhibitor, in Patients With Abnormal Cholesterol Levels. U.S. National Institutes of Health.
Ref 14 The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
Ref 15 ClinicalTrials.gov (NCT00851500) A Trial of the Safety and Efficacy of K-604 for the Treatment of Atherosclerosis. U.S. National Institutes of Health.
Ref 16 ClinicalTrials.gov (NCT01645306) Revacept in Symptomatic Carotid Stenosis (Revacept/CS/02). U.S. National Institutes of Health.
Ref 17 DVC1-0101 to treat peripheral arterial disease: a Phase I/IIa open-label dose-escalation clinical trial. Mol Ther. 2013 Mar;21(3):707-14.
Ref 18 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5594).
Ref 19 ClinicalTrials.gov (NCT00367692) Study Evaluating PSI-697 in Patients With Scleritis. U.S. National Institutes of Health.
Ref 20 ClinicalTrials.gov (NCT00985478) First in Man Study With SLV342. U.S. National Institutes of Health.
Ref 21 Indazole-based liver X receptor (LXR) modulators with maintained atherosclerotic lesion reduction activity but diminished stimulation of hepatic triglyceride synthesis. J Med Chem. 2008 Nov 27;51(22):7161-8. doi: 10.1021/jm800799q.
Ref 22 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002679)
Ref 23 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800012886)
Ref 24 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029634)
Ref 25 ClinicalTrials.gov (NCT01651273) A Safety Study of BMS-852927 in Subjects With Hypercholesterolemia. U.S. National Institutes of Health.
Ref 26 ClinicalTrials.gov (NCT00796575) Effects of Multiple Doses of CS-8080 in Healthy Volunteers. U.S. National Institutes of Health.
Ref 27 Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2011).
Ref 28 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7376).
Ref 29 ClinicalTrials.gov (NCT00836602) Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BMS-779788 in Healthy Subjects. U.S. National Institutes of Health.
Ref 30 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800034993)
Ref 31 Protease activated receptor 2 (PAR2) modulators: a patent review (2010-2015).Expert Opin Ther Pat. 2016;26(4):471-83.
Ref 32 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6696).
Ref 33 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1595).
Ref 34 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800012887)
Ref 35 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005302)
Ref 36 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008445)
Ref 37 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010688)
Ref 38 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008143)
Ref 39 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000343)
Ref 40 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004425)
Ref 41 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021613)
Ref 42 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008868)
Ref 43 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019399)
Ref 44 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025539)
Ref 45 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020582)
Ref 46 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800012486)
Ref 47 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025537)
Ref 48 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025982)
Ref 49 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004102)
Ref 50 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800014823)
Ref 51 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025540)
Ref 52 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800015443)
Ref 53 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004661)
Ref 54 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001648)
Ref 55 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800012955)
Ref 56 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025541)
Ref 57 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003109)
Ref 58 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025536)
Ref 59 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800022118)
Ref 60 Circadian rhythm as a therapeutic target. Nat Rev Drug Discov. 2021 Apr;20(4):287-307.
Ref 61 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800015904)
Ref 62 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800033616)
Ref 63 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800030801)
Ref 64 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017234)
Ref 65 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003719)
Ref 66 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800011586)
Ref 67 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004510)
Ref 68 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003702)
Ref 69 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001538)
Ref 70 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005136)
Ref 71 Effects of a novel 2,3-oxidosqualene cyclase inhibitor on the regulation of cholesterol biosynthesis in HepG2 cells. J Lipid Res. 1996 Jan;37(1):148-58.
Ref 72 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010990)
Ref 73 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004635)
Ref 74 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001910)
Ref 75 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004501)
Ref 76 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006465)
Ref 77 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3057).
Ref 78 F-12509A, a new sphingosine kinase inhibitor, produced by a discomycete. J Antibiot (Tokyo). 2000 May;53(5):459-66. doi: 10.7164/antibiotics.53.459.
Ref 79 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003139)
Ref 80 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017452)
Ref 81 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010267)
Ref 82 Effects of a novel 2,3-oxidosqualene cyclase inhibitor on cholesterol biosynthesis and lipid metabolism in vivo. J Lipid Res. 1997 Mar;38(3):564-75.
Ref 83 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005472)
Ref 84 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009165)
Ref 85 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003268)
Ref 86 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2763).
Ref 87 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004500)
Ref 88 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008057)
Ref 89 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006470)
Ref 90 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001533)
Ref 91 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000245)
Ref 92 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 777).
Ref 93 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007178)
Ref 94 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003588)
Ref 95 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003704)
Ref 96 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004423)
Ref 97 Toxicologic lesions associated with two related inhibitors of oxidosqualene cyclase in the dog and mouse. Toxicol Pathol. 2001 Mar-Apr;29(2):174-9.
Ref 98 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021743)
Ref 99 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008195)
Ref 100 B-535a, b and c, new sphingosine kinase inhibitors, produced by a marine bacterium; taxonomy, fermentation, isolation, physico-chemical properties and structure determination. J Antibiot (Tokyo). 2000 Aug;53(8):753-8.
Ref 101 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001907)
Ref 102 WO patent application no. 2013,1850,32, Nanotherapeutics for drug targeting.
Ref 103 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002683)
Ref 104 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2592).
Ref 105 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 59).
Ref 106 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 347).
Ref 107 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5788).
Ref 108 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1636).